A Phase III Clinical Trial Comparing TC to TAC for Women with<BR>Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 May 2017
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Pegfilgrastim
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Feb 2013 Additional lead trial centre identified as reported by M.D. Anderson Cancer Center.
- 17 Jan 2012 New source identified and integrated (M.D. Anderson Cancer Center; NSABPB46I).